# | Title | Journal | Year | Citations |
---|
1 | Lung cancer: current therapies and new targeted treatments | Lancet, The | 2017 | 2,267 |
2 | Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial | Lancet, The | 2004 | 2,248 |
3 | Nutrition and physical activity guidelines for cancer survivors | Ca-A Cancer Journal for Clinicians | 2012 | 1,600 |
4 | Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer | Journal of the National Cancer Institute | 2005 | 1,517 |
5 | Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study | Lancet Oncology, The | 2015 | 1,100 |
6 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial | Lancet Oncology, The | 2018 | 1,089 |
7 | PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project | Journal of Thoracic Oncology | 2017 | 1,067 |
8 | American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention: Reducing the Risk of Cancer With Healthy Food Choices and Physical Activity | Ca-A Cancer Journal for Clinicians | 2006 | 1,021 |
9 | Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain | New England Journal of Medicine | 2018 | 983 |
10 | Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 943 |
11 | HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Annals of Oncology | 2008 | 931 |
12 | Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer | Nature Genetics | 2012 | 906 |
13 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 848 |
14 | Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis | Lancet Oncology, The | 2011 | 847 |
15 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry | Annals of Oncology | 2019 | 842 |
16 | Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia | Cancer Discovery | 2016 | 799 |
17 | Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 762 |
18 | Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2016 | 760 |
19 | Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 758 |
20 | Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2006 | 701 |
21 | Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2018 | 691 |
22 | Molecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid Nodules | Journal of Clinical Endocrinology and Metabolism | 2009 | 674 |
23 | Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 672 |
24 | Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices | Ca-A Cancer Journal for Clinicians | 2006 | 649 |
25 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) | Cancer Discovery | 2017 | 647 |
26 | Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study | Lancet Oncology, The | 2016 | 607 |
27 | Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer | Journal of Thoracic Oncology | 2012 | 585 |
28 | Localization of Bronchial Intraepithelial Neoplastic Lesions by Fluorescence Bronchoscopy | Chest | 1998 | 565 |
29 | Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 564 |
30 | Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 562 |
31 | Small-cell lung cancer: what we know, what we need to know and the path forward | Nature Reviews Cancer | 2017 | 558 |
32 | Prostate Cancer, Version 1.2016 | Journal of the National Comprehensive Cancer Network: JNCCN | 2016 | 544 |
33 | Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab | Science Translational Medicine | 2011 | 543 |
34 | Interrogating open issues in cancer precision medicine with patient-derived xenografts | Nature Reviews Cancer | 2017 | 527 |
35 | Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer | Nature Medicine | 2013 | 526 |
36 | Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy | Blood | 2013 | 524 |
37 | Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification | Journal of Clinical Endocrinology and Metabolism | 2008 | 520 |
38 | Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial | Lancet, The | 2016 | 512 |
39 | Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia | Blood | 2010 | 503 |
40 | Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 498 |
41 | Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial | Lancet Oncology, The | 2012 | 487 |
42 | Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines | Cancer Research | 2006 | 482 |
43 | Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 477 |
44 | Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology | Clinical Cancer Research | 2001 | 468 |
45 | Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 451 |
46 | Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma | Journal of Clinical Oncology | 2022 | 446 |
47 | Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2018 | 432 |
48 | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial | Lancet Oncology, The | 2015 | 431 |
49 | 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? | Cancer | 2017 | 428 |
50 | Epidemiology of prostate cancer | Urology | 2003 | 421 |